PRESENTATION
Q3 2023 — Presentation
Q3 2023PDF · 31 pages2.0 MB
Merck Q3 2023 Earnings October 26, 2023 -- 1 of 31 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 31 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 31 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 31 -- Delivered on our key strategic priorities in Q3 2023 5 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to augment pipeline Created long-term value for patients and shareholders & -- 5 of 31 -- 2021 2022 2023 Strong Q3 sales performance and earnings growth 1 6 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. 3. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an aggregate $11.6 billion or $4.52 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun-Biotech. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, guidance includes an additional $5.5 billion or $1.70 per share related to the collaboration with Daiichi Sankyo, and guidance does not assume any additional significant potential business development transactions. 4. GAAP EPS of $1.86. $16.0B +7% +8% ex-Exchange, ex-LAGEVRIO 2 Q3 Worldwide Sales $2.13 +15% Q3 Non-GAAP EPS3,4 $48.7B +17% $5.37 Full Year Sales Full Year Non-GAAP EPS3 $59.3B +22% GUIDANCE RANGE $59.7B - $60.2B 2021 2022 2023 GUIDANCE RANGE $1.33 - $1.38 $5.37 $7.48 -- 6 of 31 -- Oncology Highlights Cardiometabolic Highlights • KEYNOTE-671: Received FDA approval for KEYTRUDA for the neoadjuvant and adjuvant treatment of certain patients with resectable non-small cell lung cancer • ESMO: Compelling data presented across a wide range of molecules, tumor types and indications • Sotatercept: FDA accepted for priority review the BLA for sotatercept for the treatment of adults with pulmonary arterial hypertension based on STELLAR • MK-0616: Started Phase 3 program for oral PCSK9 inhibitor candidate 7 Advancing and enhancing our deep pipeline -- 7 of 31 -- Continuing to deliver on our purpose for patients 8 $4.2B +20% $3.4B +31% $5.3B +30% $4.8B +27% $5.8B +24% Pursuing transformative science to save and improve lives around the world -- 8 of 31 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 31 -- Strong underlying Q3 worldwide sales growth 10 Merck WORLDWIDE SALES1,2 $16.0B+7% growth +6% ex-LAGEVRIO3 +8% ex-exchange, ex-LAGEVRIO3 $14.3B +10% growth +9% ex-LAGEVRIO3 +10% ex-exchange, ex-LAGEVRIO3 Human Health $1.4B +2% growth +2% ex-exchange Animal Health 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. -- 10 of 31 -- Oncology: KEYTRUDA continues to drive exceptional growth 11 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $6.3B increased 17% year-over-year, driven by global uptake in earlier stage cancers and continued strong global demand from metastatic indications – In the U.S., growth of 14% reflects strong utilization across metastatic indications and earlier stage cancers, such as TNBC – Ex-U.S., 22% increase driven by uptake in earlier stage cancers, including high-risk early- stage TNBC and adjuvant RCC, as well as increased demand in advanced RCC and certain types of H&N cancer $4.2B +20% $3.4B +31% $5.3B +30% 3Q21 3Q22 3Q23 $5.4B +26% $4.5B +21% $6.3B +17% -- 11 of 31 -- Oncology: Solid performance across broad portfolio • Lynparza 1 sales grew 6% driven primarily by pricing in the U.S. and increased demand in Latin America • Lenvima 2 sales grew 30% driven by timing of shipments in China and increased demand in advanced RCC and endometrial cancer indications in the U.S. $248M +34% $178M +62% $275M +17% $181M +15% $151M +57% $231M +33% 12 Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 3Q21 3Q22 3Q23 3Q21 3Q22 3Q23 $284M +23%$246M +25% $299M +6% $202M +11% $188M +30% $260M +30% -- 12 of 31 -- Vaccines: Robust growth driven by GARDASIL 13 • GARDASIL sales of $2.6B increased 16% year-over-year driven by strong demand, particularly in China – In the U.S., sales decreased due to the timing of CDC purchases • Strong uptake of the pediatric indication of VAXNEUVANCE in the U.S. and launches in key European markets $1.2B +78% $656M -24% $1.7B +40% 3Q21 3Q22 3Q23 $2.3B +20%$2.0B +63% $2.6B +16% Growth rates exclude the impact of foreign exchange. -- 13 of 31 -- Hospital: Contributions from key products 14 • BRIDION sales of $424M were flat as greater share among neuromuscular blockade reversal agents in the U.S. was offset by the impact of generic entry primarily in Europe • PREVYMIS sales grew 38% driven by continued strong global demand $387M +67% $224M -18% $426M +15% 3Q21 3Q22 3Q23 $423M +22% $369M +15% $424M +0% $93M +41%$63M +67% $103M +18% $94M +20% $82M +31% $129M +44% Growth rates exclude the impact of foreign exchange. 3Q21 3Q22 3Q23 $114M +29% $96M +22% $157M +38% -- 14 of 31 -- Animal Health: Growth driven by livestock 15 • Animal Health sales increased 2% to $1.4B – Livestock growth of 7% reflects price actions and increased demand for ruminant, poultry and swine products – Companion Animal sales declined 4% due to a reduction in vet visits in the U.S., partially offset by pricing actions $1.5B +27% $1.1B +3% $1.5B +5% 3Q21 3Q22 3Q23 $1.4B +4% $1.4B +14% $1.4B +2% Growth rates exclude the impact of foreign exchange. -- 15 of 31 -- Q3 2023 non-GAAP financial results summary 1 Q3 2023 Q3 2022 Change Change Ex-FX Sales $16.0 $15.0 +7% +9% Non-GAAP Gross Margin 77.0% 77.0% -0.1pts +0.8pts Non-GAAP Operating Expenses $5.8 $6.0 -4% -3% Non-GAAP Tax Rate 15.0% 13.6% +1.4pts N/A Non-GAAP EPS2,3 $2.13 $1.85 +15% +22% $ in billions, except EPS amounts 16 1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2022 includes $690 million of R&D expense for collaborations and licensing agreements with Moderna, Orna and Orion, or $0.22 of negative impact to EPS. 3. Q3 2023 GAAP EPS of $1.86. -- 16 of 31 -- Merck updated full-year 2023 guidance 1. Updated guidance includes an aggregate $17.1 billion of R&D expenses related to the Prometheus and Imago acquisitions, and upfront payments for the license and collaboration agreement with Kelun-Biotech and collaboration agreement with Daiichi Sankyo. Guidance does not assume any additional significant potential business development transactions. 2. Updated guidance includes $6.22 of one-time charges related to the Prometheus and Imago acquisitions and upfront payments to Kelun-Biotech and Daiichi Sankyo. 17 Prior Guidance Updated Guidance Key Assumptions Revenue $58.6B to $59.6B -1% to +1% (+1% to +3% ex-FX) $59.7B to $60.2B +1% to +2% (+3% to +4% ex-FX) • Includes approximately $1.3B of LAGEVRIO revenue • Ex-LAGEVRIO, growth of 9% to 10% (11 to 12% ex-FX) • Assumes ~2 ppt FX headwind Non-GAAP Gross Margin Rate ~77.0% ~77.0% Non-GAAP Operating Expenses1 $34.0B to $34.6B $39.8B to $40.4B • Includes additional $5.5B related to upfront charge for the collaboration with Daiichi Sankyo as well as investment to advance the assets Other (Income) / Expense ~$100M of expense ~$200M of expense • Includes updated FX expectations and higher net interest expense related to the Daiichi Sankyo collaboration Tax Rate ~30.5% to 31.5% ~39.0% to 40.0% • Includes ~24.5 ppt impact related to business development activity Shares Outstanding ~2.55B ~2.55B • Assumes modest share repurchase Non-GAAP EPS2 $2.95 to $3.05 $1.33 to $1.38 • Includes $1.70 one-time charge for the Daiichi Sankyo collaboration and an additional $0.04 to advance the assets and finance the transaction • Assumes 6 ppt FX headwind (additional $0.05 headwind) -- 17 of 31 -- 18 Continue to invest in our pipeline and business while augmenting our pipeline with value enhancing business development $2.6 $0.9 $1.9 $0.1 $0.5 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase $ Billions1 1. Reflects Q3 spend. Remain committed to balanced capital allocation strategy Capital allocation order of priority -- 18 of 31 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 19 of 31 -- Continuing to advance our oncology strategy Precision Molecular Targeting Impact pathways that can drive cancer growth Tissue Targeting Increase cancer cell sensitivity with ADCs and immune-engagers Immuno-oncology Boost anti-tumor immune responses 20 -- 20 of 31 -- 21 Broadening and advancing our ADC presence Data presented at ESMO from Phase 3 study evaluating KEYTRUDA in combination with enfortumab vedotin in 1L locally advanced or metastatic urothelial carcinoma KEYNOTE-A39 / EV-3023 1. Planning to submit a biologics license application (BLA) in the U.S. by the end of March 2024 based on the Phase 2 HERTHENA-Lung01 data in EGFRm NSCLC that has progressed after EGFR TKI and platinum-based therapies 2. Shows tumor types currently being studied in various phases of development 3. Trial conducted in collaboration with Seagen and Astellas Generic Name Phase 1 CDH6 Ovarian Target Status DS-6000 (R-DXd) Phase 3 1 HER3 EGFRm NSCLC, Breast U3-1402 (HER3-DXd) Phase 2 B7H3 ES-SCLC, Advanced Solid Tumors DS-7300 (I-DXd) Current Tumor Types2 Raludotatug deruxtecan Patritumab deruxtecan Ifinatamab deruxtecan MK-2870 MK-1200 1 additional clinical asset Phase 1 Claudin 18.2 GI Tumors Phase 3 TROP2 NSCLC, Breast Phase 1 Undisclosed Undisclosed Undisclosed Sacituzumab tirumotecan Collaborator Daiichi Sankyo Kelun Biotech Daiichi Sankyo Daiichi Sankyo Kelun Biotech Kelun Biotech Undisclosed -- 21 of 31 -- Sharing data from our earlier stage oncology program 22 Women’s Cancers • KEYNOTE-671: • Presented positive overall survival data at ESMO from Phase 3 study • KEYTRUDA is the first and only anti-PD(L)-1 therapy to demonstrate statistically significant improvement in OS and EFS as perioperative treatment for resectable stage II, IIIA or IIIB NSCLC versus pre- operative chemotherapy • OS benefit generally consistent across majority of subgroups • 6th KEYTRUDA indication for NSCLC to receive FDA approval • Presented positive data at ESMO: • KEYNOTE-756 in patients with ER+ HER2- breast cancer • KEYNOTE-522 in patients with high-risk early-stage TNBC • KEYNOTE-A18 in patients with high-risk locally advanced cervical cancer • FDA granted priority review with target action date of January 20 th Lung Bladder • KEYNOTE-123: • Announced Phase 3 trial evaluating KEYTRUDA for the adjuvant treatment of certain patients with localized muscle- invasive urothelial carcinoma and locally advanced urothelial carcinoma significantly improved disease-free survival -- 22 of 31 -- 23 Leveraging precision medicine to improve outcomes for patients 1. In collaboration with Taiho and Astex MK-10841 • Presented data at ESMO from Phase 3 LITESPARK-005 study for treatment of adults with previously treated advanced RCC, which showed statistically significant and clinically meaningful improvement in progression-free survival vs. everolimus (standard of care) • FDA granted priority review with target action date of January 17 th • Proceeding with additional Phase 3 studies • Presented data at ESMO for oral KRAS inhibitor as monotherapy in solid tumors and in combination with KEYTRUDA in patients with metastatic NSCLC whose tumors harbored KRAS G12C mutations WELIREG MK-3543 • Began enrolling patients in Phase 3 study evaluating bomedemstat (LSD1 inhibitor) in 2L essential thrombocythemia -- 23 of 31 -- Europe Japan • Granted approval for KEYNOTE-091 for adjuvant treatment of certain patients with NSCLC • Granted approval for KEYNOTE-811 for 1L treatment of patients with certain gastric or gastroesophageal junction adenocarcinoma • Received approval for Lynparza1 in combination with abiraterone and prednisone for treatment of certain adult patients with BRCA-mutated metastatic castration-resistant prostate cancer based on Phase 3 PROpel study 24 Bringing new cancer treatments to patients around the world 1. In collaboration with AstraZeneca -- 24 of 31 -- Vaccines Cardiometabolic • V116: • STRIDE-3 data will be presented at World Vaccine Congress West Coast on November 28th • If approved, V116 would be the first pneumococcal conjugate vaccine designed to address serotypes responsible for the majority of adult invasive pneumococcal disease Significant advancements across our broader pipeline and portfolio • Sotatercept: • Presented post-hoc analysis from STELLAR and interim analysis from SOTERIA, an open label extension study in PAH • FDA granted priority review for Biologics License Application with target action date of March 26th • Completed submission to EMA in the European Union • MK-0616: • Initiated Phase 3 CORALreef Lipids study in broad patient population with hypercholesterolemia • Initiated Phase 3 CORALreef HeFH study for patients with heterozygous familial hypercholesterolemia • Enrollment has begun for CORALreef Outcomes study measuring time to first occurrence of major atherosclerotic cardiovascular events in high risk patients Immunology • MK-7240: • Beginning to enroll patients in Phase 3 study for treatment of patients with ulcerative colitis 25 -- 25 of 31 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 26 of 31 -- Appendix 27 -- 27 of 31 -- Q3 2023 GAAP financial results summary 28 Q3 2023 Q3 2022 Change Change Ex-FX Sales $16.0 $15.0 +7% +9% Operating Expenses $5.8 $6.9 -16% -16% Tax Rate 15.5% 9.2% +6.3pts N/A GAAP EPS $1.86 $1.28 +45% +55% $ in billions, EPS amounts -- 28 of 31 -- $10.1 $4.0 $7.3 $13.1 $1.0 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.76 $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 $3.20 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Dollars per share +2% +2% +2% +2% +2% +11% +15% +7% Over the past 12 months Capital investments 2023 to 2027 Commitment to the dividend 29 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% Order of priority +6% E 1. Includes payments reflected in operating cash flow 1 -- 29 of 31 -- Driving value for patients and shareholders by progressing our pipeline 30 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S.: o FDA accepted for priority review the sNDA for WELIREG for the treatment of patients with advanced RCC immune checkpoint and anti-angiogenic therapies based on LITESPARK-005 o FDA accepted for priority review the sBLA for KEYTRUDA in combination with concurrent chemoradiotherapy for the treatment of patients with newly diagnosed high-risk locally advanced cervical cancer based on KN-A18 o Received FDA approval for KEYTRUDA in the perioperative setting for the treatment of certain patients with resectable NSCLC based on KN-671 o FDA approved KEYTRUDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell cancer based on KN-017 and KN-913 o FDA accepted for priority review the BLA for sotatercept for the treatment of patients with PAH based on STELLAR o FDA approved an expanded indication for ERVEBO for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older • In the EU: o Received EMA approval for KEYTRUDA in combination with trastuzumab and chemotherapy as 1L treatment in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in PD-L1 positive patients based on KN-811 o Received EMA approval for KEYTRUDA in patients with adjuvant NSCLC based on KN-091 o Received positive CHMP opinion for KEYTRUDA in combination with chemotherapy for 1L treatment of certain patients with locally advanced unresectable or metastatic HER2- gastric or GEJ adenocarcinoma based on KN-859 o Received EMA approval for an expanded indication for ERVEBO for active immunization of individuals 12 months of age and older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus • In Japan: o Received approval of Lynparza 1 in certain patients with BRCA-mutated castration-resistant prostate cancer o Accepted for review the sJNDA for KEYTRUDA in the perioperative setting for the treatment of patients with resectable NSCLC based on KN-671 1. In collaboration with AstraZeneca 2. Trial conducted in collaboration with Seagen and Astellas 3. In collaboration with Eisai 4. In collaboration with Moderna 5. In collaboration with Kelun-Biotech 6. In collaboration with Taiho and Astex • Presented data across broad oncology portfolio at ESMO, including for KEYTRUDA (KN-A392, KN-671, KN-A18, KN- 522, KN-756, KN-811), Lenvima3, Lynparza1, WELIREG (LITESPARK-005), V940/mRNA-41574 (INT), MK- 2870/SKB2645 (TROP2 ADC) and MK-10846 (KRAS G12C) • Announced Phase 3 KN-123 trial met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma after surgery • Presented new analyses from studies of sotatercept at ERS, including post-hoc analysis of right heart catheterization and echocardiography data from the STELLAR study and interim analysis of the Phase 3 SOTERIA open-label extension study • Advanced broad pipeline, including: o Initiated Phase 3 clinical program for MK-0616, an oral PCSK9 inhibitor o Poised to initiate Phase 3 trials for V940 4 in NSCLC, MK-2870 5 in NSCLC and MK-7240 in UC -- 30 of 31 -- Phase 2 Phase 3 Under regulatory review Oncology V181 Dengue Virus Vaccines Infectious diseases MK-8189 4 Schizophrenia Neuroscience Gefapixant (MK-7264) Cough (US) PREVYMIS (MK-8228) Prophylaxis of CMV in kidney transplant patients (EU) General medicine General medicine As of October 26, 2023 Infectious diseases Oncology Oncology MK-6024 (efinopegdutide) NASH MK-8591B (islatravir+MK-8507) 1 HIV-1 Infection MK-8591D (islatravir+lenacapavir) 2 HIV-1 Infection KEYTRUDA (MK-3475) CSCC (EU) Hepatocellular (EU) Mesothelioma Ovarian SCLC MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308A (quavonlimab +pembrolizumab) RCC MK-7684A (vibostolimab +pembrolizumab) Melanoma NSCLC SCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies LENVIMA (MK-7902) Esophageal Gastric LYNPARZA (MK-7339) NSCLC SCLC WELIREG (MK-6482) RCC (EU) TUKYSA (MK-7119) Breast CRC MK-3475A (pembrolizumab +hyaluronidase) NSCLC V940 Melanoma MK-8591A (doravirine+islatravir) 2 HIV-1 Infection KEYTRUDA (MK-3475) 2L HCC (US) LA Cervical (US) Resectable NSCLC (EU, JPN) 1L HER2- Gastric (US, EU, JPN) 1L Biliary (US, EU, JPN) WELIREG (MK-6482) Advanced RCC (US) MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease Cardiovascular MK-4830 CRC Esophageal Melanoma NSCLC Ovarian RCC SCLC MK-5684 Prostate MK-5890 (boserolimab) NSCLC SCLC LYNPARZA (MK-7339) Advanced Solid Tumors LENVIMA (MK-7902) Biliary HNSCC Pancreas Prostate SCLC KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) NSCLC MK-4280A (favezelimab+pembroli zumab) Bladder cSCC Esophageal Melanoma RCC SCLC WELIREG (MK-6482) Biliary Certain VHL tumors (EU) CRC Endometrial Esophageal HCC Pancreatic Rare Cancers TUKYSA (MK-7119) Advanced Solid Tumors Bladder Biliary Cervical Endometrial Gastric NSCLC MK-7684A (vibostolimab +pembrolizumab) Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Ovarian Prostate MK-0482 NSCLC MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC SCLC MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies NSCLC Ovarian Pancreas MK-2870 Neoplasm Malignant Broad and innovative pipeline to address significant unmet medical needs 31 Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma Note: Pipeline does not include the three DXd ADCs from the collaboration with Daiichi Sankyo MK-7962 (sotatercept) Pulmonary Arterial Hypertension (EU) Cardiovascular V116 Pneumococcal vaccine, adult MK-7240 Ulcerative Colitis Immunology MK-0616 Hypercholesterolemia MK-7962 (sotatercept) Pulmonary Arterial Hypertension (US) Cardiovascular LAGEVRIO (MK-4482) 3 COVID-19 antiviral -- 31 of 31 --